An Open-Label, Randomized, Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) study

  • Markman, Ben (Primary Chief Investigator (PCI))
  • Briggs, Peter (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

SERP Reference Number: HREC/15/SVHM/81.
SSA Reference Number: SSA/15/MonH/121.
Monash Health HREC Ref: 15418X
StatusFinished
Effective start/end date3/06/19 → 2/06/24

Keywords

  • clinical trial
  • treatment efficacy
  • lung cancer